This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Follow the science. As Dr. Koffman’s wife, caregiver, and co-founder of CLL Society, I am delighted that Cancer Health has added a glimpse of our personal story to their growing leukemia diary, sharing the humanity behind the numbers. However, as I read this I was reminded of the stunning fact that without Brian’s relentless attention to the evolving data from clinical trials and the ever-scrutinizing scholarship he brings to it, he would not be alive today. Stick close to CLL Society. Follow the science.
If you have not yet had an opportunity to learn about the personal CLL journey of our Co-Founder, Chief Medical Officer, and Executive Vice-President, we invite you to read “A Leukemia Diary: Brian Koffman MD,” published by Cancer Health.
It seems that for some patients, an additional round of CAR-T offers a second chance at meaningful remission. We refer you to a small study published in the journal, BLOOD, demonstrating that “conditioning” therapy (chemotherapy given before the infusion of CAR-T cells), as well as a higher dose of infused CAR-T cells, led to longer persistence of re-engineered cells and better outcomes. Learn more by reading, “Factors Associated with Outcomes After a Second CD19-Targeted CAR-T Cell Infusion for Refractory B-Cell Malignancies, Including Chronic Lymphocytic Leukemia.”
CLL Society’s COVID-19 Virtual Community Meeting: The Delta Variant and Staying Protected Friday, September 24, 2021, 9:00 AM PT, 10:00 AM MT, 11:00 AM CT, 12:00 PM ET
As we enter the fall, the global COVID-19 pandemic continues to wreak havoc in the US due to increased prevalence of the COVID-19 Delta variant, coupled with suboptimal vaccination rates. It is critical that CLL patients and their caregivers continue to receive credible, up-to-date information across a spectrum of expert voices, as we strategize to minimize risk to our vulnerable, immunocompromised community. Join us on Friday, September 24th for this COVID-19 Virtual Community Meeting as part of CLL Society’s continuing series, providing information to empower our CLL patients and caregivers to make safe and informed decisions related to potential exposure. Attendees can engage in a question-and-answer town hall format with our panel, featuring CLL experts Drs. Deborah Stephens and Nicole Lemanna, Infectious Disease expert Dr. Sanjeet Singh Dadwell, and PhD virologist Dr. Daniel Engel. Register here.
Question: What do you do with a “Toolkit?” Answer: Open it and pull out the tool you need, when you need it! CLL Society’s Patient Education Toolkit is now available online. We hope this is helpful!
Blood Cancer Awareness Month
September is Blood Cancer Awareness Month. Throughout September, the CLL community gains space to raise awareness, bolster education, and share stories about their disease. We are proud to be celebrating Blood Cancer Awareness Month alongside the CLL community. We are also excited to be a part of three awareness days during the month of September that are all connected to chronic lymphocytic leukemia: World CLL Day (September1st), World Leukemia Day (September 4th), and World Lymphoma Awareness Day (September 15th). Please visit CLL Society’s page dedicated to Blood Cancer Awareness Month.
In Case You Missed It
Have you relapsed on, or become refractory to, a Btk inhibitor drug such as ibrutinib, or the bcl-2 inhibitor venetoclax? If so, PI3 kinase inhibitors, such as duvelisib or idelalisib (FDA approved), or umbralisib (still in clinical trials) are worthy of consideration. CLL Society’s August 26th webinar on this topic, “Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise?” featuring Dr. Ian Flinn is offered on demand.
The LLS Co-Pay Assistance Program offers financial assistance up to $8,000 for treatment-related expenses for eligible U.S. patients whether they are in active treatment, being monitored for watch and wait, or are in follow-up care. This program can reimburse medical insurance premiums, as well as cover non-diagnostic scans, lab work, and testing, ECGs, EKGs, x-rays, ultrasounds, MRI, PET & CT scans, blood work, biopsies, bone marrow aspirations, tissue typing & stem cell harvesting for transplants, etc. Prescribed medications that can be covered including chemotherapy (IV or Oral) and supportive medications like anti-nausea, antibiotics, steroids, pain medication, and more. Apply now!
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.